Maldives vs Viet Nam: Statin use vs. average non-HDL cholesterol levels
Maldives
3.5
in 2018
Viet Nam
3.5
in 2018
Maldives rank
52nd
Viet Nam rank
52nd
Statin use vs. average non-HDL cholesterol levels over time
- Maldives
- Viet Nam
How they compare
Maldives currently reports 3.5 against 3.5 in Viet Nam, a difference of 0.
The two have swapped places 2 times across 39 shared years of data; in 1980 it was Viet Nam ahead.
Maldives ranks 52nd and Viet Nam ranks 52nd of 191 countries.
Maldives has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Maldives | Viet Nam | Difference | Ahead |
|---|---|---|---|---|
| 1980s | 2.93 | 2.81 | 0.12 | Maldives |
| 1990s | 3.09 | 2.93 | 0.16 | Maldives |
| 2000s | 3.28 | 3.12 | 0.16 | Maldives |
| 2010s | 3.47 | 3.39 | 0.0778 | Maldives |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher statin use vs. average non-hdl cholesterol levels, Maldives or Viet Nam?
- Maldives, at 3.5 against 3.5 in Viet Nam as of 2018.
- What is the difference in statin use vs. average non-hdl cholesterol levels between Maldives and Viet Nam?
- 0, with Maldives ahead.
- How many years of comparable data are there for Maldives and Viet Nam?
- 39 years are reported by both, from 1980 to 2018.
- How do Maldives and Viet Nam rank globally for statin use vs. average non-hdl cholesterol levels?
- Maldives ranks 52nd and Viet Nam ranks 52nd of 191 countries.
- Where does this data come from?
- World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data, published as Statin use vs. average non-HDL cholesterol levels. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The use of statins in the population. This is compared to average non-HDL cholesterol levels, in mmol/L. Statins are a type of drug that reduce non-HDL cholesterol levels, and are used to treat and prevent cardiovascular diseases in people at heightened risk. Their usage is measured in Defined Daily Doses, per 1,000 people.